CureVac partners with Sanofi Pasteur to develop RNActive platform
A research proposal with total funding of $33.1m involving a collaboration among CureVac, Sanofi Pasteur and In-Cell-Art, a French biotech company contributing its nanoparticle technology, has been selected
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.